Asia Pacific ELISA Diagnostics Tests Market Forecast to 2030 - Regional Analysis - by Adoption, Test Type, Application, and End User

The Asia Pacific ELISA diagnostics tests market was valued at US$ 255.70 million in 2022 and is expected to reach US$ 503.08 million by 2030; it is estimated to grow at a CAGR of 8.8% from 2022 to 2030.

Innovative Product Launches Bolster Asia Pacific ELISA Diagnostics Tests Market

ELISA is one of the most popular immunoassay tests owing to its various advantages such as flexibility, sensitivity, and easy-to-use features. Also, low cost of ELISA test kit and multifaceted applicability associated with high-throughput testing make it an ideal solution for various research and IVD requirements. With low-cost applicability, product innovations in the test kits enhance the demand for human and animal research. Also, manufacturers focus on developing ELISA test kits with in-house facilities. Innovative Research company sells a wide range of ELISA kits with selectivity to a broad range in identifying coagulants, species, and antibodies. "Human Factor IX Kit" is one such example manufactured by Innovative Research. The human coagulation Factor IX antigen assay is intended for the quantitative determination of total Factor IX antigen in human plasma. The kit is recommended to use only for research purposes, and reagents can be utilized for up to 96 clinical tests. Additionally, innovative product launches for ELISA tests by the manufacturers amid the COVID-19 pandemic accelerate the adoption of ELISA testing among humans. In December 2022, Pictor Limited announced a new product launch of the "PictArray SARS-CoV-2 Antibody Test," which has demonstrated real clinical utility intended for patients and doctors. The new product detects the infection associated with the COVID-19 virus, and the clinical results produced assist the patients and doctors in treating and managing SARS-CoV-2 infection. Launches of innovative ELISA test kits by manufacturers are expected to provide effective clinical results for diagnosing varied infections associated with different types of species with low cost and multifaceted applications. Thus, innovative product launches would provide lucrative opportunities for manufacturers in the long run.

Asia Pacific ELISA Diagnostics Tests Market Overview

China has a strong and resilient public health system that can rapidly prevent, detect, and respond to infectious disease threats before they become epidemics. China's ecology poses a risk for emerging, re-emerging, and novel diseases that could threaten China and the Rest of world owing to the vast population of ~ 1.4 billion and 50% of the world's livestock. In an article published by Journal of Global Health in September 2023, a study was carried out on annual incidence and fatality rates of notifiable infectious diseases in Jiangsu province of southeast China. The study concluded that public health policies have been effective in reducing the incidence of intestinal, vector-borne, and zoonotic diseases during the study period and the associated fatality, but that the incidence of sexually transmitted and blood-borne diseases, mainly syphilis and AIDS, has increased.

Additionally, growing network of air travel routes across the world dramatically increases the risk of rapid infection spread, including infections that may lead to pandemics, such as the COVID-19 pandemic, that result in disruption of global trade, rise in illness cases, or increase in deaths. The country is expected to provide lucrative opportunities to local and international players involved in ELISA diagnostics test market in the country.

Asia Pacific ELISA Diagnostics Tests Market Segmentation

The Asia Pacific ELISA diagnostics tests market is segmented based on adoption, test type, application, end user, and country. Based on adoption, the Asia Pacific ELISA diagnostics tests market is bifurcated into human and veterinary. The human segment held a larger market share in 2022.

In terms of test type, the Asia Pacific ELISA diagnostics tests market is segmented into sandwich ELISA, indirect ELISA, competitive ELISA, and multiple & portable ELISA. The indirect ELISA segment held the largest market share in 2022.

Based on application, the Asia Pacific ELISA diagnostics tests market is segmented into autoimmune diseases, infectious diseases, cancer diagnosis, protein quantification, and others. The infectious diseases segment held the largest market share in 2022.

By end user, the Asia Pacific ELISA diagnostics tests market is segmented into hospitals & diagnostic centers, pharmaceutical & biotechnology companies, veterinary hospitals & diagnostic laboratories, and others. The hospitals & diagnostic centers segment held the largest market share in 2022.

Based on country, the Asia Pacific ELISA diagnostics tests market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific ELISA diagnostics tests market share in 2022.

Bio-Rad Laboratories Inc., Idexx Laboratories Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corp., Pictor Ltd., DiaSorin SpA, Elabscience Biotechnology Inc., and Bio-Techne Corp are some of the leading companies operating in the Asia Pacific ELISA diagnostics tests market.